The FDA approved a new indication for Breyanzi on Dec. 4, making it the first CAR T-cell therapy in the U.S. for adults with marginal zone lymphoma who have relapsed or failed treatment after at least two prior lines of therapy.
Three notes:
1. Marginal zone lymphoma is a rare cancer that accounts for 7% of all B-cell non-Hodgkin lymphoma, with about 7,460 new diagnoses each year in the U.S.
2. In a multicenter clinical trial, 95.5% of patients who received the therapy responded to treatment, and 62.1% achieved a complete response, showing no signs of disease on imaging. Responses remained durable after a median follow-up of 21.6 months.3. Breyanzi, developed by Juno Therapeutics, received priority review and orphan drug designation from the FDA.
“Today’s approval represents a major advancement in precision medicine, essentially turning the patient’s immune system into a more effective tool to treat MZL,” said Vinay Prasad, MD, chief medical and scientific officer and director of the FDA’s Center for Biologics Evaluation and Research,, in a Dec. 4 news release. “The FDA continues to optimize its regulatory authority to expand treatment options in the fight against cancer.”
At the Becker's Perioperative Summit, taking place September 14–15 in Chicago, perioperative leaders and healthcare executives will focus on improving operating room efficiency, enhancing patient safety, optimizing staffing and driving innovation across surgical services. Apply for complimentary registration now.
